ASRS 2021: ARCHWAY and TENAYA/LUCERNE

New Retina Radio by Eyetube · Oct 22, 2021 · 16m

We may be on the cusp of the next great era of wet AMD therapy. Which phase 3 data will guide physician decision-making if new technologies are approved by regulatory bodies? Chirag Jhaveri, MD, spoke with New Retina Radio about anatomic data collected in the phase 3 ARCHWAY study. How did patients who received the Port Delivery System with Ranibizumab (PDS, Genentech) differ from those on monthly ranibizumab (Lucentis, Genentech) in terms of fluctuation in central subfield thickness? And as FDA weighs the possible approval of faricimab for the treatment of wet AMD, we hear from Karl Csaky…